BMC Infectious Diseases

Table 1 Protective efficacy against culture-confirmed cholera of several risk factors

From: Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial

	B/B ^a				B/T ^b				T/T ^c
	Full ^d		Outbreak-free ^e		Full		Outbreak-free		Full		Outbreak-free
	1-HR ^f	PH test ^g	1-HR	PH test	1-HR	PH test	1-HR	PH test	1-HR	PH test	1-HR	PH test
Vaccine efficacy
ages 1 to <5 years	0.45*	0.970	0.38	0.351	0.34	0.250	0.38	0.417	0.47*	0.931	0.44*	0.780
ages 5 to <15 years	0.67**	0.016	0.84**	0.617	0.71**	0.052	0.85**	0.806	0.59**	0.028	0.72**	0.217
ages 15 years and older	0.74**	0.008	0.69**	0.023	0.73**	0.025	0.69**	0.050	0.73**	0.058	0.71**	0.046
Participant age
1 to <5 years (ref)	0.0		0.0		0.0		0.0		0.0		0.0
5 to <15 years	0.69**	0.088	0.65**	0.011	0.74**	0.069	0.78**	0.249	0.77**	0.317	0.80**	0.542
15 years and older	0.81**	0.000	0.80**	0.000	0.88**	0.011	0.89**	0.043	0.89**	0.061	0.89**	0.095
Ward of residence
ward 29 (ref)	0.0		0.0		0.0		0.0		0.0		0.0
ward 30	0.40**	0.000	0.16	0.102	0.39**	0.000	0.15	0.209	0.39**	0.000	0.15	0.243
ward 33	0.07	0.979	-0.02	0.610	0.07	0.941	-0.01	0.719	0.07	0.755	-0.01	0.751
Large cluster	-0.61	0.382	-0.43	0.026	-0.60	0.403	-0.43	0.023	-0.60	0.384	-0.42	0.025
Own house	0.24	0.189	0.34*	0.549	0.24	0.351	0.34*	0.668	0.24	0.367	0.35*	0.715
Stable occupation	0.27	0.644	0.27	0.539	0.27	0.628	0.27	0.583	0.27	0.527	0.27	0.560
High income	0.32**	0.662	0.38**	0.125	0.32**	0.784	0.38**	0.109	0.32**	0.954	0.38**	0.121
Far from water	-0.31	0.013	-0.09	0.476	-0.31	0.025	-0.08	0.627	-0.31	0.044	-0.09	0.683
Global test ^h		0.000		0.003		0.004		0.312		0.004		0.233
Log lik ratio ⁱ				106				122				118

^aboth vaccine and age effect are estimated for age group at baseline
^bvaccine effect is estimated for age group at baseline, age effect is estimated using time-dependent age groups
^cboth vaccine effect and age effect are estimated using time-dependent age groups
^dall participants were included
^eparticipants with events during March–April 2010 were excluded
^f1-hazard ratio, which can be interpreted as the protective efficacy for the vaccine effect. Significant terms (p< 0.05) are marked with * and highly significant terms (p< 0.01) are marked with **
^gp from test of proportional hazards (PH) assumption
^hglobal test of proportional hazards assumption
ⁱlog likelihood ratio relative to a Cox model with no covariate

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com